|
1.
|
|
|
2.
|
|
10 p, 4.1 MB |
Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment
/
Rubio-Perez, Carlota (Vall d'Hebron Institut d'Oncologia) ;
Planas-Rigol, Ester (Vall d'Hebron Institut d'Oncologia) ;
Trincado, Juan L. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bonfill-Teixidor, Ester (Vall d'Hebron Institut d'Oncologia) ;
Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ;
Marchese, Domenica (Centre de Regulació Genòmica) ;
Moutinho, Catia (Centre de Regulació Genòmica) ;
Serna, Garazi (Vall d'Hebron Institut d'Oncologia) ;
Pedrosa, Leire (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Iurlaro, Raffaella (Vall d'Hebron Institut d'Oncologia) ;
Martinez-Ricarte, Fran (Universitat Autònoma de Barcelona) ;
Escudero, Laura (Vall d'Hebron Institut d'Oncologia) ;
Cordero, Esteban (Universitat Autònoma de Barcelona) ;
Cicuendez, Marta (Universitat Autònoma de Barcelona) ;
Ruiz, Sara (Centre de Regulació Genòmica) ;
Parra, Genís (Centre de Regulació Genòmica) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Gonzalez, Josep (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Pineda, Estela (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Sahuquillo Barris, Juan (Universitat Autònoma de Barcelona) ;
Tabernero, Josep (Centro de Investigación Biomédica en Red de Cáncer) ;
Heyn, Holger (Universitat Pompeu Fabra) ;
Seoane Suárez, Joan (Institució Catalana de Recerca i Estudis Avançats)
Brain metastases are the most common tumor of the brain with a dismal prognosis. A fraction of patients with brain metastasis benefit from treatment with immune checkpoint inhibitors (ICI) and the degree and phenotype of the immune cell infiltration has been used to predict response to ICI. [...]
2021 -  10.1038/s41467-021-21789-x
Nature communications, Vol. 12 (march 2021)
|
|
|
3.
|
|
6 p, 916.0 KB |
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
/
De Mattos-Arruda, Leticia (Universitat Autònoma de Barcelona) ;
Mayor, Regina (Vall d'Hebron Institut d'Oncologia) ;
Ng, Charlotte K. Y. (Memorial Sloan Kettering Cancer Center) ;
Weigelt, Britta (Memorial Sloan Kettering Cancer Center) ;
Martinez-Ricarte, Fran (Universitat Autònoma de Barcelona) ;
Torrejon, Davis (Vall d'Hebron Institut d'Oncologia) ;
Oliveira, Mafalda (Vall d'Hebron Institut d'Oncologia) ;
Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ;
Raventós, Carolina (Vall d'Hebron Institut d'Oncologia) ;
Tang, Jiabin (Memorial Sloan Kettering Cancer Center) ;
Guerini-Rocco, Elena (Memorial Sloan Kettering Cancer Center) ;
Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Lois, Sergio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Marín, Oscar (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
de la Cruz, Xavier (Institució Catalana de Recerca i Estudis Avançats) ;
Piscuoglio, Salvatore (Memorial Sloan Kettering Cancer Center) ;
Towers, Russel (Department of Surgery, Memorial Sloan Kettering Cancer Center) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Ramón y Cajal, Santiago (Universitat Autònoma de Barcelona) ;
Carles, Joan (Vall d'Hebron Institut d'Oncologia) ;
Rodon, Jordi (Vall d'Hebron Institut d'Oncologia) ;
González-Cao, María (Quirón Dexeus University Hospital) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Felip, Enriqueta (Universitat Autònoma de Barcelona) ;
Sahuquillo Barris, Juan (Universitat Autònoma de Barcelona) ;
Berger, Michael F. (Memorial Sloan Kettering Cancer Center) ;
Cortés, Javier (Universitat Autònoma de Barcelona) ;
Reis-Filho, Jorge S. (Memorial Sloan Kettering Cancer Center) ;
Seoane Suárez, Joan (Universitat Autònoma de Barcelona)
Cell-free circulating tumour DNA (ctDNA) in plasma has been shown to be informative of the genomic alterations present in tumours and has been used to monitor tumour progression and response to treatments. [...]
2015 - 10.1038/ncomms9839
Nature communications, Vol. 6 (november 2015)
|
|
|
4.
|
|
12 p, 5.0 MB |
Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
/
Vicario, Rocío (Vall d'Hebron Institut d'Oncologia) ;
Peg, Vicente (Hospital Universitari Vall d'Hebron) ;
Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ;
Zacarías-Fluck, Mariano F (Vall d'Hebron Institut d'Oncologia) ;
Zhang, Junjie (Vall d'Hebron Institut d'Oncologia) ;
Martínez-Barriocanal, Águeda (Vall d'Hebron Institut d'Oncologia) ;
Navarro Jiménez, Alexandra (Hospital Universitari Vall d'Hebron) ;
Aura, Claudia (Vall d'Hebron Institut d'Oncologia) ;
Burgués, Octavio (Hospital Clínic Universitari (València)) ;
Lluch, Ana (Hospital Clínic Universitari (València)) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Rubio, Isabel T. (Vall d'Hebron Institut d'Oncologia) ;
Marangoni, Elisabetta (Institut Curie) ;
Deeds, James (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ;
Boehm, Markus (Novartis Pharma AG (Suïssa)) ;
Schlegel, Robert (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ;
Boehm, Markus (Novartis Pharma AG (Suïssa)) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Mosher, Rebecca (Novartis Oncology Translational Research (Estats Units d'Amèrica)) ;
Boehm, Markus (Novartis Pharma (Suïssa)) ;
Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ;
Universitat Autònoma de Barcelona
A chromosomal region that includes the gene encoding HER2, a receptor tyrosine kinase (RTK), is amplified in 20% of breast cancers. Although these tumors tend to respond to drugs directed against HER2, they frequently become resistant and resume their malignant progression. [...]
2015 - 10.1371/journal.pone.0129876
PloS one, Vol. 10 (june 2015)
|
|
|
5.
|
|
5 p, 332.1 KB |
Biosimilars : a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers
/
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Vyas, Malvika (European Society for Medical Oncology) ;
Giuliani, Rosa (San Camillo Forlanini Hospital) ;
Arnold, Dirk (CUF Hospitals) ;
Cardoso, Fatima (Champalimaud Clinical Center) ;
Casali, Paolo G. (Fondazione IRCCS National Cancer Institute) ;
Cervantes, Andrés (Clinic Hospital) ;
Eggermont, Alexander (Gustave Roussy Cancer Campus Grand Paris) ;
Eniu, Alexandru (Cancer Institute "Ion Chiricuta") ;
Jassem, Jacek (Medical University of Gdansk) ;
Pentheroudakis, George (University of Ioannina) ;
Peters, Solange (Centre Hospitalier Universitaire Vaudois) ;
Rauh, Stefan (Hospital Center Emile Mayrisch) ;
Zielinski, Christoph C. (Medical University of Vienna) ;
Stahel, Rolf A. (Netherlands Cancer Institute) ;
Voest, Emile (University Hospital Zurich (Suïssa)) ;
Douillard, Jean-Yves (European Society for Medical Oncology) ;
McGregor, Keith (European Society for Medical Oncology) ;
Ciardiello, Fortunato (Second University of Naples) ;
Universitat Autònoma de Barcelona
Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare systems. If suitably developed clinically, manufactured to the correct standards and used appropriately, they can positively impact on the financial sustainability of healthcare systems. [...]
2017 - 10.1136/esmoopen-2016-000142
ESMO open, Vol. 1 (january 2017)
|
|
|
6.
|
|
5 p, 324.7 KB |
The European Cancer Patient's Bill of Rights, update and implementation 2016
/
Højgaard, Liselotte (Kobenhavns Universitet) ;
Löwenberg, Bob (Erasmus University Medical Center) ;
Selby, Peter (University of Leeds) ;
Lawler, Mark (European Cancer Concord) ;
Banks, Ian (University of Leeds) ;
Law, Kate (European Cancer Concord) ;
Albreht, Tit (Institut za varovanje zdravja Republike Slovenija) ;
Armand, Jean-Pierre (Gustave Roussy) ;
Barbacid, Mariano (Centro Nacional de Investigaciones Oncológicas) ;
Barzach, Michèle (IHU Strasbourg Board of Trustees) ;
Bergh, Jonas (Karolinska Institutet (Estocolm, Suècia)) ;
Cameron, David (University of Edinburgh) ;
Conte, Pierfranco (Istituto Oncologico Veneto) ;
de Braud, Filippo (National Cancer Institute) ;
de Gramont, Aimery (Institut Hospitalier Franco-Britannique) ;
De Lorenzo, Francesco (European Cancer Patient Coalition) ;
Diehl, Volker (Universitat zu Koln) ;
Diler, Sarper (Myeloma Patients Europe) ;
Erdem, Sema (Europa Donna) ;
Geissler, Jan (European Patients Academy on Therapeutic Innovation) ;
Gore-Booth, Jola (EuropaColon) ;
Henning, Geoffrey (EuropaColon) ;
Horgan, Denis (European Alliance for Personalised Medicine) ;
Jassem, Jacek (Medical University of Gdansk) ;
Johnson, Peter (Cancer Research UK) ;
Kaasa, Stein (Norges Teknisk-Naturvitenskapelige Universitet) ;
Kapitein, Peter (Inspire2Live) ;
Karjalainen, Sakari (Association of European Cancer Leagues) ;
Kelly, Joan (Irish Cancer Society) ;
Kienesberger, Anita (Austrian Childhood Cancer Organisation) ;
La Vecchia, Carlo (Universita degli Studi di Milano) ;
Lacombe, Denis (European Organisation for Research and Treatment of Cancer) ;
Lindahl, Tomas (Francis Crick Institute) ;
Luzzatto, Lucio (Universita degli Studi di Firenze) ;
Malby, Rebecca (London South Bank University) ;
Mastris, Ken (Europa Uomo) ;
Meunier, Françoise (European Organisation for Research and Treatment of Cancer) ;
Murphy, Martin (Society for Translational Oncology) ;
Naredi, Peter (European Cancer Organisation) ;
Nurse, Paul (Francis Crick Institute) ;
Oliver, Kathy (International Brain Tumour Alliance) ;
Pearce, Jonathan (Lymphoma Association) ;
Pelouchov, Jana (European Cancer Patient Coalition) ;
Piccart, Martine (Institut Jules Bordet) ;
Pinedo, Bob (VuMC Cancer Center) ;
Spurrier-Bernard, Gilly (Melanoma Patient Network Europe) ;
Sullivan, Richard (Kings Health Partners Integrated Cancer Centre) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Van de Velde, Cornelis (Leids Universitair Medisch Centrum) ;
van Herk, Bert (Spaarne Gasthuis) ;
Vedsted, Peter (Aarhus Universitet) ;
Waldmann, Anita (Leukaemiehilfe RHEIN-MAIN) ;
Weller, David (University of Edinburgh) ;
Wilking, Nils (Skåne University Hospital (Suècia)) ;
Wilson, Roger (Sarcoma Patients EuroNet EV) ;
Yared, Wendy (Association of European Cancer Leagues) ;
Zielinski, Christoph C (European Society for Medical Oncology) ;
zur Hausen, Harald (University of Heidelberg) ;
Le Chevalier, Thierry (Institute Gustave Roussy) ;
Johnston, Patrick (European Cancer Concord) ;
Universitat Autònoma de Barcelona
In this implementation phase of the European Cancer Patient's Bill of Rights (BoR), we confirm the following three patient-centred principles that underpin this initiative: The key aspects of working towards implementing the BoR are:.
2017 - 10.1136/esmoopen-2016-000127
ESMO open, Vol. 1 (january 2017)
|
|
|
7.
|
|
|
8.
|
|
8 p, 594.9 KB |
Preparing for the incoming wave of biosimilars in oncology
/
Wolff-Holz, Elena (Federal Institute for Vaccines and Biomedicines) ;
Garcia Burgos, Juan (European Medicines Agency) ;
Giuliani, Rosa (San Camillo Forlanini Hospital) ;
Befrits, Gustaf (Stockholm County Council) ;
de Munter, Johan (Universitair Ziekenhuis Gent) ;
Avedano, Luisa (European Federation of Crohn's & Ulcerative Colitis Associations) ;
Aitken, Murray (IQVIA Institute for Human Data Science) ;
Gonzalez-Quevedo, Rosa (European Medicines Agency) ;
Vyas, Malvika (European Society for Medical Oncology) ;
De Vries, Elisabeth G. E. (University Medical Center Groningen) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
With the imminent arrival of oncology biosimilars in the therapeutic paradigm, stakeholders including a clinician, specialist nurse, patient advocate, regulator and economist provide their perspective on optimising the uptake of these new agents in the treatment of cancer. [...]
2018 - 10.1136/esmoopen-2018-000420
ESMO open, Vol. 3 (september 2018)
|
|
|
9.
|
|
10 p, 384.2 KB |
Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy
/
Ilson, David H. (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Prokharau, Aliaksandr (Minsk City Clinical Oncology Dispensary) ;
Arkenau, Hendrik-Tobias (University College London) ;
Ghidini, Michele (Azienda Ospedaliera di Cremona) ;
Fujitani, Kazumasa (Osaka General Medical Center) ;
Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Thuss-Patience, Peter (Charité - Universitätsmedizin Berlin) ;
Beretta, Giordano D. (Humanitas Gavazzeni) ;
Mansoor, Wasat (The Christie NHS Foundation Trust (Regne Unit)) ;
Zhavrid, Edvard (Alexandrov National Cancer Centre of Belarus) ;
Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ;
George, Ben (Medical College of Wisconsin) ;
Catenacci, Daniel (University of Chicago) ;
McGuigan, Sandra (Taiho Oncology Inc) ;
Makris, Lukas (Stathmi Inc) ;
Doi, Toshihiko (National Cancer Center Hospital East (Japó)) ;
Shitara, Kohei (National Cancer Center Hospital East (Japó)) ;
Universitat Autònoma de Barcelona
This subgroup analysis of a randomized clinical trial compares trifluridine/tipiracil treatment with placebo for progression-free and overall survival among patients with previously treated metastatic gastric or gastroesophageal junction cancer who had or had not undergone gastrectomy. [...]
2019 - 10.1001/jamaoncol.2019.3531
JAMA Oncology, Vol. 6 (october 2019)
|
|
|
10.
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
